Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study

INTRODUCTION: This subgroup analysis of data from the 16-week Lantus Registry Study in China investigated the characteristics of patients with type 2 diabetes mellitus (T2DM) associated with clinical benefits of transitioning therapy from premixed insulin to insulin glargine (100 U/ml) plus oral ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Bu, Shi, Zhang, Xuelian, Zhu, Haiqing, Shuai, Ying, Xing, Xiaoyan, Yang, Wenying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544620/
https://www.ncbi.nlm.nih.gov/pubmed/28623551
http://dx.doi.org/10.1007/s13300-017-0284-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544620/
https://www.ncbi.nlm.nih.gov/pubmed/28623551
http://dx.doi.org/10.1007/s13300-017-0284-1

Ejemplares similares